The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Reading Rheum: Which Bone Agent Is Best in High-risk Osteoporosis?

Reading Rheum: Which Bone Agent Is Best in High-risk Osteoporosis?

March 1, 2008 • By Eric S. Schned, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Osteoporosis

Which Bone Agent Is Best in High-risk Osteoporosis?

By Eric S. Schned, MD

You Might Also Like
  • Reading Rheum
  • Women on Osteoporosis Drugs Still Need Bone Density Screenings
  • Romosozumab Improves Bone Mineral Density in Men with Osteoporosis
Explore This Issue
March 2008
Also By This Author
  • Reading Rheum

Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med. 2007;357:2028-2039.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Abstract

Background: Bisphosphonate therapy is the current standard of care for the prevention and treatment of glucocorticoid-induced osteoporosis (GIO). Studies of anabolic therapy in patients who are receiving long-term glucocorticoids (GCs) and are at high risk for fracture are lacking.

Methods: In an 18-month randomized, double-blind, controlled trial, we compared teriparatide with alendronate in 428 women and men with osteoporosis (ages 22 to 89) who had received GCs for at least three months (prednisone equivalent, 5 mg daily or more). A total of 214 patients received 20 μg of teriparatide once daily, and 214 received 10 mg of alendronate once daily. The primary outcome was the change in bone mineral density at the lumbar spine (LS). Secondary outcomes included changes in bone mineral density at the total hip and in markers of bone turnover, the time to changes in bone mineral density, the incidence of fractures, and safety.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Results: At the last measurement, the mean (±SE) bone mineral density at the LS had increased more in the teriparatide group than in the alendronate group (7.2±0.7% versus 3.4±0.7%, p<0.001). A significant difference between the groups was reached by six months (p<0.001). At 12 months, bone mineral density at the total hip had increased more in the teriparatide group. Fewer new vertebral fractures occurred in the teriparatide group than in the alendronate group (0.6% versus 6.1%, p=0.004); the incidence of nonvertebral fractures was similar in the two groups (5.6% versus 3.7%, p=0.36). Significantly more patients in the teriparatide group had at least one elevated measure of serum calcium.

Conclusions: Among patients with osteoporosis who were at high risk for fracture, bone mineral density increased more in patients receiving teriparatide than in those receiving alendronate.

Commentary

Rheumatologists know intimately the hazards of long-term GC therapy. GIO and resultant fractures are especially vexing problems since some patients in whom we use GCs are already at high risk for these complications. These patients include postmenopausal women with long-standing RA or lupus and elderly patients with polymyalgia rheumatica (PMR) and giant cell arteritis (GCA).

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Bisphosphonate therapy is the current standard of care for patients who already have—or are at risk for developing—GIO.1 Bisphosphonates act primarily on bone resorption, however, while teriparatide directly stimulates osteogenesis and inhibits osteoblast apoptosis, two key mechanisms in bone affected by GCs.2 These actions make teriparatide a good candidate for treating or preventing GIO.

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, DMARDs & Immunosuppressives, Research Reviews Tagged With: anabolic, Bisphosphonate, Clinical research, glucocorticoid, Osteoporosis, randomized controlled trial, riskIssue: March 2008

You Might Also Like:
  • Reading Rheum
  • Women on Osteoporosis Drugs Still Need Bone Density Screenings
  • Romosozumab Improves Bone Mineral Density in Men with Osteoporosis
  • Serum Bone Markers CTX, PINP Not Linked with Hip Fracture Risk in Osteoporosis

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.